London (Reuters) – GlaxoSmithKline reiterated his plan to ask
authorization regulatory to commercialize his new medication
pulmonary key Relovair to mid-2012, despite spreading
on Friday another series of joint trials results.
The new inhalable daily decision-making drug showed
superiority to the current drug of two shots per day
Advair – sobre also of GSK-in one of the trials the
chronic lung disease, but not in the other.
These mixed results replicated those from other studies
obtained in an extensive development program.
However, the greatest British laboratory remains confident
in the product. Hopes that the convenient single daily dose of
pill attracts patients and help to position
better as a replacement for Advair, which has annual revenues of
more than 8,000 million dollars and is the largest product in
sales of GSK.
The company said that Relovair being developed
along with Theravance, seek approval against the disease
pulmonary obstructive chronic (COPD) in United States and Europe to
mid this year.
Authorization as a treatment for asthma will also be asked
in Europe at the same time. In United States, GSK will continue to
discussing the use of the medicinal product with the regulators in
patients with asthma.
